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Abstract
Purinergic signalling regulates airway defence mechanisms, suggesting that extracellular purines
could serve as airway inflammation biomarkers in cystic fibrosis (CF).
The purines adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine
monophosphate (AMP) and adenosine were measured in sputum from 21 adults (spontaneously
expectorated from seven CF patients, induced from 14 healthy controls) to assess normal values and
CF-associated changes. Subsequently, purine levels were measured in bronchoalveolar lavage fluid
(BALF) from 37 children (25 CF patients, 12 disease controls) and compared with neutrophil counts,
presence of airway infection and lung function. To noninvasively assess airway purines, ATP levels
were measured using luminometry in exhaled breath condensate (EBC) from 14 children with CF
and 14 healthy controls, then 14 CF children during a pulmonary exacerbation.
Both ATP and AMP were elevated in sputum and BALF from CF subjects compared with controls.
In BALF, ATP and AMP levels were inversely related to lung function and strongly correlated with
neutrophil counts. In EBC, ATP levels were increased in CF relative to controls and decreased after
treatment of CF pulmonary exacerbation.
The purines adenosine triphosphate and adenosine monophosphate are candidate biomarkers of
neutrophilic airways inflammation. Measurement of purines in sputum or exhaled breath condensate
may provide a relatively simple and noninvasive method to track this inflammation.
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Extracellular adenyl purines, including the purine nucleotide adenosine triphosphate (ATP)
and its metabolites, are important signalling molecules on airway surfaces. These purines serve
as agonists for purinergic signal-ling pathways that play critical roles in airway mucus
clearance. Indeed, ATP-mediated signal-ling regulates airway surface liquid volume, ciliary
function and mucin secretion [1–3], each critical for control of mucus clearance rates.
Purines also mediate multiple components of inflammatory cell responses that are part of lung
defence. For example, pro-inflammatory stimuli enhance release of ATP from epithelial [4–
6] and inflammatory cells [7–10]. In particular, stimulated neutrophils release ATP and
accumulate both extracellular ATP and adenosine monophosphate (AMP) [10,11].
Inflammation also affects airway-luminal extracellular purine metabolism, both by altering
ectonucleotidase activity on epithelial cell surfaces [12] and by addition of ectonucleotidase
activity associated with the accumulation of inflammatory cells [8]. ATP released onto airway
surfaces in response to inflammation also stimulates inflammatory cell responses, including
chemotaxis and degranulation in neutrophils [10,13–15], cytokine production and oxidative
bursts in macrophages [16–18], and activation of lymphocytes and eosinophils [17]. Adenosine
formed as a consequence of ATP release also acts as a signalling molecule with both pro-
inflammatory and anti-inflammatory effects [19,20].
The importance of purinergic signalling in lung inflammation has been demonstrated in vivo.
For example, ATP receptor (P2Y1-R and P2Y2-R)-deficient mice exhibit impaired
inflammatory responses and difficulty eradicating Pseudomonas from the lung [21]. Similarly,
mouse strains with modest increases in lung adenosine have enhanced interleukin (IL)-4-
mediated inflammatory responses [22], and higher lung adenosine levels lead to airway
inflammation and pulmonary fibrosis [23,24]. In vivo studies of airway purines in humans are
limited, although increased levels of ATP have been observed in nasal lavage fluid [25] and
blood [26] of subjects with cystic fibrosis (CF), and adenosine levels in airway secretions are
elevated in untreated asthma and correlate with disease state [27–29].
The role of purines as mediators of the inflammatory response suggests that they may also be
markers of inflammation. However, the concentrations and pattern of extracellular adenyl
purines in the normal and diseased human airways surface remain largely unexplored. The aim
of the present study was to measure the levels of purines in human airway secretions and
evaluate their potential as biomarkers of airway inflammation, particularly in children with
CF. First, purine levels were measured in sputum to establish normal values and assess changes
associated with CF. In addition, purine levels were measured in the supernatant of
mucopurulent material (SMM) aspirated from CF lungs removed for transplantation.
Following this, bronchoalveolar lavage fluid (BALF) was collected from children undergoing
clinically indicated bronchoscopy, and correlations were sought between purines and
established markers of airways disease, including neutrophil counts, presence of infection and
lung function. Finally, a simple and noninvasive method to measure airway purines in children
by measuring ATP levels in exhaled breath condensate (EBC) was explored.
METHODS AND MATERIALS
Study subjects
Subject demographics are outlined in table 1. Control populations were healthy individuals,
except in the BALF study, which included the following disease controls: two subjects with
primary ciliary dyskinesia and 10 subjects with recurrent cough or wheeze, all of whom were
clinically stable at the time of bronchoscopy. All subjects were studied at the University of
North Carolina at Chapel Hill (Chapel Hill, NC, USA), and studies were approved by the
Institutional Review Board.
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Differences between purine levels in airway secretions were assessed by comparison of CF
with control populations. The relationship between purine levels and other markers of disease
were assessed by regression analysis.
Methods
Sputum from healthy controls was collected and processed using induction as previously
described [30]. Briefly, mucus plugs were selected, weighed and incubated with 0.1%
dithiotreitol to solubilise mucus. Sodium citrate was added at 0.32% to the sample buffers to
limit hydrolysis of purines. Samples were then washed in Dulbecco’s PBS, filtered and
analysed for cell viability, cell counts and differential. Sputum from CF subjects was collected
by spontaneous expectoration, but was processed identically to induced samples.
SMM was recovered from the airway lumen of 13 excised human CF lungs at the time of
transplant [31]. This material was centrifuged at 440,000 × g for 60 min at 4°C and the
supernatant filtered through a 0.2-µm filter and frozen at −80°C.
BALF was obtained via clinically indicated bronchoscopy. Aliquots were placed on ice,
centrifuged at 11,000 × g for 5 min at 4°C to remove cells and bacteria, and the supernatant
immediately frozen and stored at −80°C. Separate aliquots were processed for cell differential
and quantitative microbiological culture.
EBC was collected using an RTube™ device (Respiratory Research, Inc., Charlottesville, VA,
USA). The chiller tube was held at −10°C until immediately before the collection, and the
subject exhaled through the device during 7 min of tidal breathing. No nose clips were used.
EBC was recovered from the RTube™ and frozen at −80°C until analysis.
Purine analysis—Adenyl purines were measured in airway secretions using etheno-
derivatisation and HPLC [32]. Samples were boiled for 2 min prior to analysis, to inactivate
nucleotidases.
Luminometry—The luciferin–luciferase assay was a modification of a previously described
protocol [33]. In brief, 100 µL aliquots from each sample were analysed in the light chamber
of an LB953 AutoLumat luminometer (Berthold Technologies GmbH, Bad Wildbad,
Germany) after a 100 µL injection of a luciferin–luciferase cocktail (luciferin 160 µg·mL−1
and luciferase 8 µM). Luminescence was recorded for 10 s and compared with an ATP
calibration curve performed in parallel.
Analysis—All data are expressed as mean±SE, except demographic information, which is
reported as mean±SD. Data that did not follow a normal distribution by D’Agostino–Pearson
tests were log-transformed prior to analysis, including all purine measurements and neutrophil
counts. Comparisons between groups were performed using unpaired t-tests, except for pre-
and post-antibiotic comparisons, which were performed on paired data. Correlations were
performed using Pearson’s correlation.
RESULTS
Purine levels in normal induced sputum and CF sputum
To establish normal purine levels and assess whether these were altered in CF, purines were
measured in sputum collected by induction from 14 healthy adults and spontaneously
expectorated from seven adult CF subjects. Given the relationship between purines and
inflammation, it was hypothesised that sputum purines would be elevated in subjects with CF,
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a disease characterised by high levels of airway inflammation. Purines were measured using
etheno-derivatisation and HPLC, a technique which has been successfully utilised to measure
purines from a variety of biological fluids [32]. Assessment of recovery and metabolism of
purines in sputum revealed that purines could be readily recovered and measured in both control
and CF sputa (recovery rates: 89 and 81% for control and CF, respectively), and that purine
metabolism during processing could be limited by addition of sodium citrate to the sample (for
further details see supplementary data).
Analysis of sputa revealed the expected increase in neutrophilic inflammation in the CF sputa
compared with control (14,700 versus 240 neutrophils·mg−1 sputum, respectively; p=0.01).
Differences in the pattern and concentration of purines were also observed. Analysis of purine
concentrations in normal sputa revealed a pattern of adenosine ≈ AMP> adenosine diphosphate
(ADP)>ATP. In contrast, CF sputa contained increased levels of both ATP and AMP, but not
ADP or adenosine, relative to controls (fig. 1a). Indeed, the ATP to adenosine ratio was elevated
in sputa from CF subjects compared with control (mean±SE: 33.0±6.6 versus 0.99±0.2,
respectively; p=0.003), as was the AMP to adenosine ratio (1.85±0.4 versus 0.08±0.0 for CF
and control, respectively; p=0.007). To ensure that the induction procedure in controls did not
affect the results, purine levels were examined in paired spontaneously expectorated and
induced sputum samples from three individuals (one CF patient and two with chronic
obstructive pulmonary disease). Purine levels were actually modestly higher (approximately
two-fold) in the induced samples, suggesting that the differences between CF and control could
not be attributed to use of induction in the control population (data not shown).
To assess whether these findings were reproducible in airway secretions not accessible to
expectoration, SMM obtained from the airways of explanted CF lungs at the time of
transplantation was obtained. The pattern of purines in the SMM from 13 explanted CF lungs
was similar to that observed in CF sputum, with proportionally higher levels of AMP and
relatively low levels of adenosine (fig. 1b). Thus, the pattern of purines in CF secretions
appeared to be independent of sample collection technique.
Airway purines were elevated in BALF from children with airways disease and correlated
with neutrophilic bronchitis
The present authors wished to determine whether the relation-ship between purines and airways
disease could also be observed in children. Due to the frequent inability of children to
expectorate sputum, airway secretions were obtained using bronchoalveolar lavage (BAL).
BALF was prospectively collected and analysed from 25 children with CF and 12 non-CF
subjects (disease controls; DC). Similar to the previous data, higher levels of both ATP and
AMP were observed in CF BALF, compared with DC BALF, with AMP present at the highest
absolute concentration (fig. 2a). Neither ADP nor adenosine levels differed among the groups.
While higher levels of ATP and AMP were observed in BALF from CF subjects, it could not
be distinguished whether the differences were CF specific or reflected the higher levels of
airway bacterial infection and/or neutrophilic bronchitis that characterise CF airways disease
[34]. To determine the variables most closely correlated with purine levels, a multiple
regression model was used to assess whether CF status, presence of airway infection (>50,000
pathogens·mL−1 on BALF culture) or neutrophil cell count best predicted ATP or AMP levels
in BALF. In the resulting model, only neutrophilic counts emerged as a significant predictor
of ATP or AMP levels, with strong correlations to both ATP and AMP (fig. 2b). In contrast,
neutrophil counts were not strongly correlated with either adenosine (r= −0.22, p=0.19) or ADP
(r=0.25, p=0.14). Similar correlations were observed in the sputum samples between neutrophil
counts and both ATP and AMP (r=0.75, p=0.0007 and r=0.81, p=0.0001, respectively),
although the results were limited by the small number of subjects from whom accurate cell
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counts could be obtained (three CF subjects and 14 controls). These data suggest that ATP and
AMP are primarily biomarkers of neutrophilic inflammation.
Airway purines correlated with lung function
Since neutrophilic inflammation mediates many of the clinical manifestations of CF airways
disease, including declines in lung function, the present authors tested for correlations between
purine levels in BALF and lung function. Although significant correlations were observed
between raw ATP and AMP values and lung function (data not shown), it was recognised that
variable dilution of airway secretions in BALF could confound the relationship between BALF
biomarkers and clinical outcomes. The current authors attempted to control for dilution using
the BALF to serum urea ratio, a widely used albeit problematic dilution marker [35]. However,
a correlation trend was observed between urea-based dilution factors and neutrophil counts (r=
−0.40, p=0.056), suggesting that BALF urea levels were artefactually increased in diseased
airways, perhaps by increased efflux of urea through inflamed epithelia during lavage [35].
Therefore, an alternative method to control for dilution using ratios of ATP or AMP to
adenosine was examined, since ratios are not affected by dilution. This method is based on the
observation that both ATP and AMP correlate with markers of airways disease, whereas
adenosine does not. As anticipated, significant correlations were observed for both ATP/
adenosine and AMP/adenosine ratios with the percentage of neutrophils as dilution-
independent markers of bronchitis (fig. 3a). Furthermore, significant correlations were also
seen between the purine ratios and per cent predicted forced expiratory volume in one second
(FEV1; fig. 3b). These data indicate that with appropriate methods to control for dilution,
airway ATP and AMP levels correlate with a clinically relevant index of disease severity as
expected for a biomarker of neutrophilic inflammation.
ATP in EBC was correlated with airway inflammation
While the present data demonstrated that the purines ATP and AMP are potential biomarkers
of neutrophilic inflammation in children with CF, risks and technical challenges associated
with BAL limit clinical application. To determine whether airway purines could be measured
using a simple and noninvasive method in children, the feasibility of detecting purines in EBC
was explored.
In a pilot study, EBC was obtained from a small group of healthy and CF children (four in each
group). Initial analyses using etheno-derivatisation and HPLC revealed that EBC purine
concentrations were below the etheno-derivatisation detection threshold in most individuals
(data not shown). As a more sensitive method, a highly sensitive and specific luminometry
method was utilised, which is widely used to measure ATP levels in biological samples [25,
36,37]. With luminometry, a signal above background was detected in each of the pilot EBC
samples (mean±SE (range) 840±320 (157–2,428) arbitrary light units (ALU)). Consistent with
the signal being ATP specific, the signal disappeared with sample pre-incubation for 30 min
with 2 units·mL−1 of the ATP degrading enzyme apyrase (post-treatment 15±5 ALU; fig. 4a),
but not in time-control incubations. Based on comparison to known standards, EBC ATP
concentrations were in the low picomolar range, consistent with those measured in BALF and
sputum after taking into account the 103–104 (or higher) dilution of airway secretions in EBC
[38,39]. At this concentration range, reproducibility was modest, with within-sample
coefficients of variation between 20–30%. For this reason, EBC ATP levels were reported as
the average of duplicate measures.
To further assess EBC ATP levels with the luminometric method, the pilot study was expanded
to include EBCs collected from a total of 14 children with CF and 14 healthy controls during
regular clinic visits. Consistent with the previous results, EBC ATP levels were elevated in
children with CF compared with healthy controls (fig. 4b). Treatment of a CF exacerbation
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reduces neutrophilic airway inflammation [40]; thus, it was hypothesised that EBC ATP levels
would drop during treatment. To explore this relationship, EBC was collected from 14 children
with CF at the beginning and end of a course of intravenous antibiotics for a pulmonary
exacerbation, including four CF subjects from the previous study. The mean±SD treatment
duration was 21.6±3.3 days, with antibiotics chosen by the treating physician. As expected,
lung function improved after antibiotic treatment (mean±SD FEV1 % pred: 60.1±20.1% pre-
versus 70.1±19.9% post-antibiotics, p≤0.01). This improvement was associated with a three-
fold fall in EBC ATP levels (fig. 4c), consistent with previously observed changes in sputum
markers of neutrophilic inflammation after treatment [40]. Although these data are preliminary,
they do indicate that EBC ATP levels fit the pattern expected for a biomarker of neutrophilic
inflammation.
DISCUSSION
Extracellular purines are the signalling molecules of purinergic signalling pathways that
regulate airway defences, including mucociliary clearance and intraluminal inflammatory
responses. In the present study, it was demonstrated that both the pattern and concentration of
these purines have a strong relationship to CF airways inflammation. Analyses of secretions
from CF subjects obtained as sputum, SMM and BALF provided a remarkably consistent
picture in which AMP was the dominant purine, and both ATP and AMP were elevated in CF
compared with control (table 2). This pattern of purines differed significantly from the
relatively equal levels of AMP and adenosine observed in sputum from normal subjects, which
in turn was similar to that reported in cultures of normal airway epithelia [32]. Although
subjects with CF were primarily studied, the data suggest that the relationship between purines
and neutrophilic inflammation is not CF specific. However, further study is necessary before
the present findings can be confidently generalised to non-CF airways disease.
While the source of airway purines was not identified in the present study, the strong correlation
between purine levels and neutrophil counts suggests that neutrophils may be a major
contributor to purine levels in CF airway secretions. This conclusion is consistent with previous
studies showing that activated neutrophils exhibit increased release of ATP and accumulate
AMP [41]. However, purine release from necrotic or apoptotic cells cannot be excluded, nor
can a significant contribution from inflamed airway epithelia or other inflammatory cells be
ruled out. Although bacteria are another potential source of extracellular purines, it seems
unlikely that bacteria significantly contributed to ATP release at levels commonly found in CF
sputum (~107·mL−1) [42]. The accumulation of AMP suggests a relative absence of 5’-
nucleotidase metabolism of AMP to adenosine, a pattern which has been observed in isolated
neutrophils (which lack 5’-nucleotidase) but not airway epithelia [32,43]. Therefore, the high
levels of AMP in samples obtained from diseased airways suggest that neutrophils dominate
the metabolic pattern of purine nucleotides on these airway surfaces.
Regardless of the underlying mechanism(s), the strong correlation with neutrophil counts
indicates that airway levels of ATP and AMP are potential biomarkers of neutrophilic
inflammation. The present data suggest that measurement of ATP in EBC may hold promise
as a simple and noninvasive method to assess the degree of neutrophilic airway inflammation
in children. Indeed, the approximately three-fold reduction in EBC ATP levels after treatment
of CF pulmonary exacerbation parallels the reduction of neutrophil cell counts and IL-8 levels
in sputum after similar treatment [40].
However, the current results also highlighted many of the known limitations to EBC analysis.
The measured ATP concentrations were low and near the threshold for detection, suggesting
that small technical artefacts or variations could significantly affect the results. Furthermore,
the small volumes of EBC collected precluded measurement of both ATP and dilution markers.
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Consequently, systematic differences in sample dilutions among groups could not be assessed
and could contribute to the observed differences. Therefore, further improvements in
methodology are needed for more thorough evaluation of the clinical potential of EBC purine
measurements.
While ATP and AMP emerged as potential biomarkers, similar findings were not observed for
adenosine. While the levels of adenosine in BALF were similar to previously published values
[27], the present authors did not observe the elevated levels of airway adenosine [27,28] or
correlation to disease severity previously described for asthma [29]. This difference may reflect
fundamental differences in airway pathophysiology between asthma and CF. CF is
characterised by a pathogen- and neutrophil-dominated airway inflammation that differs
significantly from the less cellular, eosinophil rich, and relatively sterile airway inflammation
observed in asthma. These findings suggest that factors responsible for increased adenosine
levels in asthma are not common in the neutrophilic bronchitis that characterises CF.
In addition to exploring the potential of airway purines as biomarkers of inflammation, the
present study also provides new insights into purinergic signalling pathways in airways disease.
While it was not possible to accurately determine the dilution in the BALF samples, both the
ATP and adenosine levels in BALF were consistent with previous reports [25,27], and previous
studies suggest that airway secretions in BALF were probably diluted 10–100-fold [35]. Given
this level of dilution, in situ ATP levels would be above the median effective concentration
(EC50) for the P2Y2 ATP receptor in airway epithelia (0.24 µM) [44] and approach the levels
needed to activate P2Y2 receptors in inflammatory cells [13,45]. These considerations suggest
that ATP-mediated purinergic signalling may be adaptively increased in bacterially infected
airways, leading to higher mucociliary clearance and greater activation of inflammatory cells.
Similarly, the average adenosine levels in both healthy and CF airways are predicted to be
above the EC50 values of the A1 and A2a adenosine receptors (0.31 and 0.73 µM, respectively)
found on inflammatory cells [46,47], although somewhat lower than the EC50 of the dominant
adenosine receptor (A2b) expressed in airway epithelia [32]. As adenosine levels did not
correlate with markers of disease, the present authors would not anticipate that adenosine-
mediated signalling would increase with neutrophilic inflammation, and the increased ATP to
adenosine ratio might favour a more pro-inflammatory environment [20]. However, recently
published evidence suggests that AMP may serve as an adenosine receptor agonist, either
directly [48] or after conversion to adenosine at the epithelial surface [49]. Thus, increased
adenosine receptor signalling, mediated through AMP, could modulate increased
inflammation.
In conclusion, the present study demonstrates that purines recovered in airway secretions are
biomarkers of neutrophilic airway inflammation and are elevated in cystic fibrosis airways
disease. The results suggest that measurement of purines in exhaled breath condensate may be
useful as a noninvasive method of assessing airway inflammation, although further refinements
are necessary.
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Airway purines were elevated in cystic fibrosis (CF). a) Sputum was obtained by spontaneous
expectoration from adults with CF (n=7; ●) and after induction in healthy controls (n=14; ○),
and purines measured in isolated supernatants. Both adenosine triphosphate (ATP) and
adenosine monophosphate (AMP) were significantly elevated in CF compared with control,
while adenosine diphosphate (ADP) and adenosine (Ado) levels were similar between groups.
b) Supernatant of mucopurulent material (SMM) was obtained from the explanted lungs of
adults with end-stage CF at time of lung transplantation (n=13). The pattern of purine levels
in SMM was similar to that observed in CF sputum. #: p<0.0001.
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Purines in bronchoalveolar lavage fluid (BALF) from children were elevated in cystic fibrosis
(CF) and correlated with neutrophilic airway inflammation. a) BALF was obtained from
children with CF (n=25; ●) and from disease controls (n=12; ○) with other respiratory diseases.
Measurement of purines in the supernatant of this BALF revealed elevated levels of adenosine
triphosphate (ATP) and adenosine monophosphate (AMP) in the CF group. b) Statistically
significant correlations were observed between polymorphonuclear neutrophil (PMN) counts
and levels of both ATP (□) and AMP (■) in BALF. ADP: adenosine diphosphate; Ado:
adenosine. #: p50.0164; ¶: p50.0300. b) ATP: r=0.81, p<0.0001; AMP: r=0.74, p<0.0001.
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Purine ratios correlated with neutrophilic airway inflammation and lung function. Ratios of
adenosine triphosphate (ATP) to adenosine (Ado; □) and adenosine monophosphate (AMP) to
Ado;■ were calculated as markers of purine levels corrected for variable dilution of airway
secretions in bronchoalveolar lavage fluid. a) Both ATP/Ado and AMP/Ado ratios were
strongly correlated with percentage of polymorphonuclear neutrophils (PMNs) as a dilution-
independent marker of inflammation. b) Purine ratios were compared with spirometry data
available from a subset of subjects (n=28, 20 cystic fibrosis and eight disease controls). Both
ATP/Ado and AMP/Ado ratios were negatively correlated with forced expiratory volume in
one second (FEV1 % predicted). a) ATP/Ado: r=0.76, p<0.0001; AMP/Ado: r=0.67, p<0.0001.
b) ATP/Ado: r= −0.41, p=0.0335; AMP/Ado: r= −0.43, p=0.0240.
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Adenosine triphosphate (ATP) in exhaled breath condensate (EBC) was elevated in cystic
fibrosis (CF) and decreased with treatment of a CF exacerbation. ATP levels in EBC were
measured by luminometry. a) Pilot EBC collections were obtained from four healthy controls
(subjects 1–4) and four CF subjects (5–8). A luminescent signal was detected in all samples
that was stable to incubation at 37°C for 30 min ( ), compared with samples kept at 0°C on
ice (■), and disappeared after incubation with 2 units·mL−1 of the ATP degrading enzyme
apyrase (□). b) ATP levels were measured in EBC from CF (n=14) and healthy controls (n=14).
ATP was elevated in the CF group. c) ATP levels in EBC were measured at the start and end
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of a course of antibiotics to treat a pulmonary exacerbation in children with CF (n=14). ATP
levels were lower at the end of treatment. ALU: arbitrary light units. #: p=0.0441;¶: p=0.0175.
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  Subjects (M/F) n 7 (3/4) 14 (6/8)
  Age yrs 26.6±7.1 26.9±5.4
  FEV1 % pred 28.3±11.6# 103.4±9.5
BALF study
  Subjects (M/F) n 25 (11/14) 12 (7/5)
  Age yrs 10.5±3.7 8.9±3.5
  FEV1 % pred 76.6±21.4¶ 104.3±24.4¶
EBC study
  Subjects (M/F) n 14 (5/9) 14 (6/8)
  Age yrs 13.8±3.3 11.9±2.8
  FEV1 % pred 77.0±26.6+ ND
EBC antibiotic study
  Subjects (M/F) n 14 (6/8)
  Age yrs 14.8±3.5
  FEV1 % pred 60.1±20.1
Data are presented as mean±SD, unless otherwise stated. CF: cystic fibrosis; M: male; F: female; FEV1: forced expiratory volume in one second; % pred:
% predicted; BALF: bronchoalveolar lavage fluid; EBC: exhaled breath condensate; ND: not determined.
#
not available for three subjects
¶
not available for four subjects
+
not available for one subject.
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TABLE 2
Relative purine composition of airway secretions
Sample ATP ADP AMP Ado
Healthy
  Sputum 2.8±0.5 9.8±1.9 36.2±4.3 51.2±4.9
CF
  Sputum 8.0±3.5 1.5±0.7 84.8±7.0 5.7±3.0
  SMM 14.1±3.1 9.1±1.9 69.5±5.5 7.2±1.7
  BALF 2.3±0.2 2.7±0.8 82.9±4.0 12.0±3.9
Data are presented as mean±se relative percentages of each purine. The pattern of airway purines was similar in the various types of airway sample, but
differed in healthy versus cystic fibrosis (CF) subjects ATP: adenosine triphosphate; ADP: adenosine diphosphate; AMP: adenosine monophosphate;
Ado: adenosine; SMM: supernatant of mucopurulent material; BALF: broncho-alveolar lavage fluid.
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